| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | MGC29565 ELISA Kit; OCIF ELISA Kit; OPG ELISA Kit; Osteoclastogenesis inhibitory factor ELISA Kit; Osteoprotegerin ELISA Kit; PDB5 ELISA Kit; TNF receptor superfamily member 11b ELISA Kit; TNFRSF 11B ELISA Kit; TNFRSF11B ELISA Kit; TR 1 ELISA Kit; TR1 ELISA Kit; TR11B_HUMAN ELISA Kit; Tumor necrosis factor receptor superfamily member 11B ELISA Kit |
| Assay Time | |
| Assay Type | |
| Detection Range | |
| Detection Wavelength | |
| Product Type | |
| Reactivity | |
| Sample Type(s) | serum, plasma, tissue homogenates |
| Sensitivity | |
| Species | |
| Target | |
| UniProt # |
Background
Osteoprotegerin (TNFRSF11B) is a biological molecule commonly studied in cell biology research. It is commonly used as a molecular readout in mechanistic and biomarker-focused studies.
UniProt: O00300
Biological context
Researchers often monitor Osteoprotegerin in serum, plasma, and tissue homogenates to better understand themes such as signal transduction pathways, cell cycle control, and stress-response programs. In many model systems, measured levels can shift with physiology, experimental perturbation, or disease-associated changes, making careful biological interpretation important.
Interpreting changes in measured levels
Depending on sample matrix and study design, increases or decreases in Osteoprotegerin may reflect differences in expression, secretion, turnover, or compartmentalization rather than a single mechanism. Interpretation is typically strengthened by evaluating related molecules (for example, phosphorylation-dependent signaling nodes, stress markers, and organelle proteins) and by keeping pre-analytical variables consistent across groups.
Nomenclature
In publications and databases, Osteoprotegerin may also appear under names such as MGC29565 and OCIF. When comparing studies, confirm that the reported analyte refers to the same molecule and species context.
Why ELISA data are widely used
ELISA is a common approach for quantitative measurement of proteins and biomarkers in complex samples, enabling comparisons across experimental groups and time points. When integrating results with other readouts, consider species biology, sample type, and the broader pathway context that Osteoprotegerin participates in.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Clinical value of miR-31-5p in predicting vascular calcification in patients with end-stage renal disease
R Li, R Guan, Y Lv,Turkish Journal of Biochemistry,2025
Bone turnover markers response to aerobic versus resistance exercise among postmenopausal Saudi women
SM Abd E-Kader, N Refaey, AG Atiaa,Journal of Medical Rehabilitation Science,2025
Mast Cell Chymase Has a Negative Impact on Human Osteoblasts
T Lind,Matrix Biology,2022
Gingival crevicular fluid levels of SLIT3 are increased in periodontal disease
Wei Zhong, et al,Oral Diseases,2019
Effect of Wnt signal-RANKL/OPG axis on the enhanced osteogenic integration of a lithium incorporated surface
Tingben Huang, et al,Biomaterials Science,2018
Bioavailable 25 (OH) D but not total 25 (OH) D is an independent determinant for bone mineral density in Chinese postmenopausal women
Li C.et al,EBioMedicine.,2017
99Tc-MDP-induced human osteoblast proliferation, differentiation and expression of osteoprotegerin
Chen J.et al,Mol Med Rep,2017
Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial.
Esteghamati A.et al,Diabetes Metab Syndr.,2015
Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes
Esteghamati A. et al,Arch Cardiovasc Dis,2015
Salivary level of RANKL and OPG in chronic periodontitis
Batool H Al-Ghurabi et al,journal of baghdad college of dentistry,2015
RANKL and OPG Serum Levels in Acute Coronary Syndrome
Ahmed Abdul-hassan Abbas. et al,Journal of Natural Sciences Research,2015
Interrelationship of Circulating Matrix Metalloproteinase-9, TNF-a, and OPG/RANK/RANKL Systems in COPD Patients with Osteoporosis
Zhang PF et al,COPD,2013
Ulinastatin Reduces Cancer Recurrence after Resection of Hepatic Metastases from Colon Cancer by Inhibiting MMP-9 Activation via the Antifibrinolytic Pathway
Bo Xu et al,BioMed Research International,2013
Heme oxygenase-1 mediates protective effects on inflammatory, catabolic and senescence responses induced by interleukin-1ß in osteoarthritic osteoblasts
Cleacuterigues V et al,Biochemical Pharmacology,2012
Osteoprotegerin expression and sensitivity in otosclerosis with different histological activity
Karosi T et al ,European Archives of Oto-Rhino-Laryngology,2011
Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis
Bai P et al,Respiratory Research,2011